Roger Adsett Sells 2,444 Shares of Insmed Incorporated (NASDAQ:INSM) Stock

Insmed Incorporated (NASDAQ:INSM) COO Roger Adsett sold 2,444 shares of the firm’s stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $65.95, for a total value of $161,181.80. Following the completion of the transaction, the chief operating officer now owns 147,666 shares in the company, valued at $9,738,572.70. The trade was a 1.63 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Roger Adsett also recently made the following trade(s):

• On Friday, January 10th, Roger Adsett sold 4,902 shares of Insmed stock. The shares were sold at an average price of $63.68, for a total transaction of $312,159.36.

Insmed Stock Down 0.7 %

Insmed stock opened at $65.25 on Friday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. The firm has a 50 day moving average price of $71.23 and a 200 day moving average price of $72.44. Insmed Incorporated has a fifty-two week low of $21.92 and a fifty-two week high of $80.53. The company has a market capitalization of $11.67 billion, a PE ratio of -11.76 and a beta of 1.12.

Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.19) by ($0.08). The firm had revenue of $93.40 million during the quarter, compared to analyst estimates of $93.36 million. During the same period in the previous year, the firm earned ($1.10) earnings per share. The company’s quarterly revenue was up 18.1% on a year-over-year basis. Research analysts expect that Insmed Incorporated will post -5.44 earnings per share for the current year.

Institutional Trading of Insmed

Hedge funds have recently made changes to their positions in the business. V Square Quantitative Management LLC purchased a new stake in Insmed during the 3rd quarter worth approximately $30,000. GAMMA Investing LLC grew its stake in shares of Insmed by 71.3% in the third quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 224 shares in the last quarter. Exchange Traded Concepts LLC raised its stake in shares of Insmed by 522.5% in the third quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock valued at $55,000 after acquiring an additional 627 shares in the last quarter. Blue Trust Inc. boosted its holdings in Insmed by 2,348.8% in the third quarter. Blue Trust Inc. now owns 1,959 shares of the biopharmaceutical company’s stock valued at $131,000 after purchasing an additional 1,879 shares during the period. Finally, JCIC Asset Management Inc. acquired a new position in Insmed during the 3rd quarter worth $133,000.

Analyst Upgrades and Downgrades

INSM has been the subject of several research reports. JPMorgan Chase & Co. upped their price objective on shares of Insmed from $74.00 to $83.00 and gave the company an “overweight” rating in a research note on Friday, November 22nd. HC Wainwright reaffirmed a “buy” rating and issued a $90.00 price target on shares of Insmed in a report on Friday, November 1st. Truist Financial reissued a “buy” rating and set a $105.00 price objective (up previously from $100.00) on shares of Insmed in a research note on Friday, November 1st. Finally, Bank of America raised their target price on Insmed from $84.00 to $86.00 and gave the stock a “buy” rating in a research note on Wednesday, October 9th. One equities research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $83.67.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.